Cargando…

Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects

The therapeutic landscape in the treatment of advanced/metastatic renal cell cancer has evolved over the last 2 years with the advent of immune checkpoint inhibitors. In 2018 and 2019, marketing authorisations valid throughout the European Union were issued for nivolumab and ipilimumab dual checkpoi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moscetti, Luca, Hennik, Paula, Bolstad, Bjorg, Camarero, Jorge, Josephson, Filip, Melchiorri, Daniela, Sommerfelt Grønvold, Maja, Sjoberg, Jan, Botezatu, Mihaela, Mulder, Jorn, Meulendijks, Didier, Trullas Jimeno, Ana, Zafiropoulos, Nikolaos, Bergh, Jonas, Enzmann, Harald, Pignatti, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451283/ https://www.ncbi.nlm.nih.gov/pubmed/32847837 http://dx.doi.org/10.1136/esmoopen-2020-000856

Ejemplares similares

European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma
por: Ali, Sahra, et al.
Publicado: (2020)

European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis
por: Tzogani, Kyriaki, et al.
Publicado: (2019)

The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements
por: Delgado, J., et al.
Publicado: (2021)

The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy
por: Trullas, A., et al.
Publicado: (2021)

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2018)

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2017)

The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
por: Trullas, A., et al.
Publicado: (2021)

The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation
por: Trullas-Jimeno, A., et al.
Publicado: (2021)

The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors
por: Tesileanu, C Mircea S, et al.
Publicado: (2023)

The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
por: Delgado, J., et al.
Publicado: (2021)

The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors
por: Araujo-Fernandez, I., et al.
Publicado: (2020)

European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer
por: Stanel, Stefan Cristian, et al.
Publicado: (2017)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Delgado, Julio, et al.
Publicado: (2021)

Notes of Four Cases of Leprosy in Minnesota
por: Gronvold, Chr.
Publicado: (1879)

Leprosy in Minnesota
por: Grönvold, Chas.
Publicado: (1884)

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
por: Delgado, Julio, et al.
Publicado: (2021)

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
por: Delgado, Julio, et al.
Publicado: (2021)

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach
por: Mulder, Jorn, et al.
Publicado: (2022)

Bach Goes to Town †
por: Christensen, Jørn Bolstad
Publicado: (2018)

Binding and entry of animal viruses
por: Sommerfelt, Maja A., et al.
Publicado: (1989)

Virtual patient simulation: what do students make of it? A focus group study
por: Botezatu, Mihaela, et al.
Publicado: (2010)

Pharmacogenetic‐Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017
por: Maliepaard, Marc, et al.
Publicado: (2020)

Current european regulatory perspectives on insulin analogues
por: Enzmann, Harald G, et al.
Publicado: (2011)

European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
por: Tzogani, Kyriaki, et al.
Publicado: (2019)

Recent Advances in Fluorescent Arylboronic Acids for Glucose Sensing
por: Hansen, Jon Stefan, et al.
Publicado: (2013)

A new donor for charge-transfer systems: synthesis and properties of 2,4,7,9-tetramethyl-1,6-dithiapyrene (TMDTP) and structure of (TMDTP)(3)(PF(6))(2)·2THF and TMDTP–TCNQ
por: Bendix, Jesper, et al.
Publicado: (2021)

Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit
por: Mulder, J., et al.
Publicado: (2023)

The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
por: Tzogani, Kyriaki, et al.
Publicado: (2017)

Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
por: Schuessler‐Lenz, Martina, et al.
Publicado: (2019)

Promoting Safe Early Clinical Research of Novel Drug Candidates: A European Union Regulatory Perspective
por: Ponzano, Stefano, et al.
Publicado: (2017)

The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
por: Cavaleri, Marco, et al.
Publicado: (2021)

The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
por: Michaleas, S., et al.
Publicado: (2022)

Green Accelerated Synthesis, Antimicrobial Activity and Seed Germination Test of Quaternary Ammonium Salts of 1,2-bis(4-pyridyl)ethane
por: Tăbăcaru, Aurel, et al.
Publicado: (2019)

The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study
por: Brekke, Kristin, et al.
Publicado: (2017)

Characterization of digital medical images utilizing support vector machines
por: Maglogiannis, Ilias G, et al.
Publicado: (2004)

Seep-carbonate lamination controlled by cyclic particle flux
por: Himmler, Tobias, et al.
Publicado: (2016)

Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer
por: Sjöberg, Elin, et al.
Publicado: (2016)

Treatment outcomes for eating disorders in Sweden: data from the national quality registry
por: Södersten, Per, et al.
Publicado: (2019)

Core Decompression for Post-Arthroscopic Osteonecrosis of the Lateral Tibial Plateau
por: Sargeant, Harry W., et al.
Publicado: (2019)

Physical activity levels of allied health professionals working in a large Australian metropolitan health district – an observational study
por: Zafiropoulos, Bill, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e0tfhhn2h03s51fj7rgcnkqvn5